Takeda Pharmaceutical Co Ltd (TKPHF) Gains from Sales and Divestitures (2019 - 2026)

Takeda Pharmaceutical's Gains from Sales and Divestitures history runs 8 years deep, the most recent figure standing at $1.2 million for Q2 2026.

• In Q2 2026, Gains from Sales and Divestitures fell 69.84% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $17.2 million (down 13.31% YoY), while the FY2026 annual figure was $20.4 million, down 30.93% from the prior year.
• Gains from Sales and Divestitures for Q2 2026 stood at $1.2 million, down from $11.4 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $27.4 million in Q1 2024, with the low at -$152337.4 in Q3 2023.
• The 5-year median for Gains from Sales and Divestitures is $2.5 million (2024), against an average of $6.2 million.
• Peak annual rise in Gains from Sales and Divestitures reached 4294.87% in 2023, while the deepest fall reached 115.25% in 2023.
• Takeda Pharmaceutical's Gains from Sales and Divestitures stood at $999194.4 in 2022, then jumped by 1040.18% to $11.4 million in 2023, then sank by 65.24% to $4.0 million in 2024, then plunged by 41.25% to $2.3 million in 2025, then tumbled by 47.68% to $1.2 million in 2026.
• Business Quant data shows TKPHF's Gains from Sales and Divestitures at $1.2 million in Q2 2026, $11.4 million in Q1 2026, and $2.3 million in Q4 2025.